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Since the discovery of microRNAs (miRNAs), different approaches have been developed
to label, amplify and quantify miRNAs. The TaqMan® technology, provided by Applied
Biosystems (ABIs), uses a stem-loop reverse transcription primer system to reverse
transcribe the RNA and amplify the cDNA. This method is widely used to identify global
differences between the expression of 100s of miRNAs across comparative samples.This
technique also allows the quantiﬁcation of the expression of targeted miRNAs to validate
observations determined by whole-genome screening or to analyze few speciﬁc miRNAs
on a large number of samples. Here, we describe the validation of a method published by
ABIs on their web site allowing to reverse transcribe and pre-amplify multiple miRNAs and
snoRNAs simultaneously. The validation of this protocol was performed on human muscle
and plasma samples. Fast and cost efﬁcient, this method achieves an easy and convenient
way to screen a relatively large number of miRNAs in parallel.
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BACKGROUND
MicroRNAs (miRNAs) are recently discovered small non-coding
RNAs (∼22 nucleotides) regulating protein expression in animals
and plants (Bartel et al., 2004). miRNAs can alter cellular func-
tion by binding the 3′-UTR of target mRNA and therefore inhibit
the expression of the corresponding protein by either repressing
protein translation or promoting mRNA degradation (Krol et al.,
2010). miRNAs can be highly and speciﬁcally enriched in spe-
ciﬁc tissues and each miRNA can target multiple mRNA species
(Lim et al., 2005; Sood et al., 2006). It is now well established that
miRNAs play a pivotal regulatory role in many cellular processes
including cell growth, proliferation, differentiation, and apopto-
sis (Bueno et al., 2008; Subramanian and Steer, 2010). miRNAs
dysregulation is reﬂective of physiological and pathological adap-
tation processes and aberrant miRNAs expression is a hallmark of
numerous disease conditions such as cancer, cardiovascular, neu-
rological, and autoimmune disorders (Lawrie et al., 2008; Gidron
et al., 2010; Caporali and Emanueli, 2011; Dai and Ahmed, 2011;
Rasheed et al., 2013). Environmental factors including nutrition,
sleep, exercise, hypoxia, and stress also contribute to the modu-
lation of miRNAs expression (Chan et al., 2009; Wang and Cui,
2012; Zacharewicz et al., 2013).
Skeletal muscle is one of the largest organ of the body, making
up approximately 40% of the whole body mass. Skeletal muscle
is a highly plastic tissue able to adapt its size, structure and func-
tion in response to various internal and external stimuli, such as
acute exercise, hypoxia, and training. miRNAs have been recently
identiﬁed as novel, essential regulators of skeletal muscle health
(Zacharewicz et al., 2013) and may account for speciﬁc regulation
of muscle growth and differentiation (Buckingham and Rigby,
2014). miRNAs localization is, however, not restricted to cells and
some miRNAs produced in cells are secreted in the bloodstream
(Chen et al., 2008). miRNAs are reported to be highly stable in both
plasma and serum (Mitchell et al., 2008) and circulating miRNAs
expression is altered in pathological conditions. Although their
role in circulation is not yet clear,miRNAs are promising biomark-
ers for the diagnostic of various pathologies, injuries and health
conditions (Chen et al., 2008; Baggish et al., 2011; Zampetaki et al.,
2012b).
The expression of speciﬁc miRNAs in tissues, including skeletal
muscle and plasma, can be assessed using the reverse transcription
quantitative real-time polymerase chain reaction (RT-qPCR). Mei
et al. (2012) already described a broad range of commercially avail-
able miRNAs RT-qPCR assays. The classical approach involves the
use of predesigned individual assays. The TaqMan® technology
provided by Applied Biosystems (ABI) uses a target-speciﬁc stem-
loop RT primer that extends the 3′ end of the targeted miRNA
to produce a cDNA template, which can then be ampliﬁed and
quantiﬁed by real-time qPCR (Chen et al., 2005). This method
is suitable for targeted quantiﬁcation and validation of miRNAs
proﬁling results. In contrast, miRNAs arrays collectively allow for
the accurate quantiﬁcation of 100s of miRNAs; a highly efﬁcient
method to establish the extended miRNAs expression proﬁle of
multiple tissue samples. However, miRNAs arrays are not suitable
for the analysis of a small number of miRNAs on a large number
of samples. Although the use of individual assays seems to be the
most appropriate approach for this type of analyzes, the reverse
transcription (RT) and quantiﬁcation of each individual miRNA
is time and reagent consuming. Recently, ABI described on their
web site (Protocol for Creating Custom RT and Preampliﬁcation
Pools using TaqMan® MicroRNA Assays User Bulletin (Pub. no.
4465407 Rev. C) – cms_094060.pdf, 2014) a method allowing to
multiplex the RT and pre-ampliﬁcation (PA) steps. To our knowl-
edge, this method was never validated in the literature. The aim
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of the present study was to validate and adapt this protocol on
human muscle and plasma samples.
DESCRIPTION OF METHODS
METHOD DESIGN
In this report, we describe and validate a modiﬁed TaqMan® Small
RNA Assay method allowing the simultaneous RT followed by
the PA of multiple miRNAs in both human muscle and plasma
samples. The different steps of the method for each type of sample
are depicted in Figure 1. The low amount of RNA in plasma
justiﬁes the addition of a PA step prior to the real-time qPCR
to enhance the sensitivity of the reaction. Irrespectively of the
tissue used ABI suggests to perform a PA step for any starting
RNA amount smaller than 350 ng. Previous experiments from
our lab demonstrated that a PA step is not necessary with skeletal
muscle tissue as muscle miRNAs concentration is generally high
enough to yield reliable results. We consequently decided to apply
the PA step to plasma tissue only. The RT primer pool designed to
analyze muscle and plasma miRNAs consisted in 11 (miR-1, miR-
15a, miR-16, miR-21, miR-126, miR-133a, miR-210, miR-221,
miR-222, RNU44, and RNU48) and 8 (miR-16, miR-20a, miR-21,
miR-126, miR-133a, miR-146a, miR-210, and miR-454) miRNA
speciﬁc primers sets, respectively. These miRNAs were selected on
the basis of their relevance and expression levels in human muscle
and plasma, respectively (Mitchell et al., 2008; Baggish et al., 2011;
Davidsen et al., 2011; Zampetaki et al., 2012a; Aoi et al., 2013; Bye
et al., 2013; Nielsen et al., 2014). In each type of sample, four
miRNAs were further selected to complete the validation process.
SAMPLES COLLECTION AND HANDLING
Muscle
Biopsies from the vastus lateralis muscle were obtained from four
healthy subjects participating in a study previously published by
our group (Faiss et al., 2013).
Plasma
Blood samples were obtained from four healthy subjects partici-
pating in a study previously published by our group (Faiss et al.,
2013). Peripheral blood samples were collected from the antecu-
bital vein in 2 × 2.6 ml EDTA tubes (Sarstedt S-Monovette) using
a butterﬂy device. The samples were immediately centrifuged at
3500 g at 4◦C for 10min and the upper phasewas collected. Plasma
samples were then frozen in liquid nitrogen and stored at −80◦C
until further processing.
RNA EXTRACTION
Muscle
Total RNA from skeletal muscle sample (approximately 25 mg of
muscle) was isolated using a commercially available preparation,
TriReagent® (Molecular Research Center, Inc., Cincinnati, OH,
USA), following the manufacturer’s instructions and as previously
published by our group (Léger et al., 2006). Brieﬂy, tissue samples
were homogenized in 500 μl TriReagent® with a power homog-
enizer (Polytron® System PT2100, Kinematica AG, Lucerne) and
incubated for 5 min at room temperature (R.T). Following this,
100 μl of chloroform were added and the sample was mixed dur-
ing 20 s before being incubated for 10 min at R.T. After a 20 min
centrifugation at R.T (12’000 g), 250 μl isopropanol were added
to the aqueous phase and the sample was mixed for 20 s. Sam-
ples were precipitated overnight at −20◦C and then centrifuged
for 30 min at 4◦C (12’000 g). RNA pellet was washed with 75%
ethanol before being resuspended in 20 μl dH2O and stored at
−80◦C until use.
Plasma
Plasma aliquots were thawed on ice and centrifuged at 10’000 g for
10 min at 4◦C to remove any remaining cellular contents. 400 μl
of plasma were used for total RNA extraction using the mirVana
PARIS kit (Life Technologies, Ambion, #AM1556) following the
FIGURE 1 | Method design.
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manufacturer’s protocol with minor modiﬁcations. Brieﬂy, 400 μl
of 2×denaturing solution and 800 μl of acid-phenol:chloroform
were added to the plasma. Following this, the samples were vor-
texed for 60 s and incubated for 10 min on ice. After 20 min of
centrifugation at 13’000 g at 4◦C, the supernatant was collected
and 1 ml of 100% ethanol was added. The lysate/ethanol mixture
was then transferred onto a ﬁlter cartridge and centrifuged for
15 s at 10’000 g at R.T. Filter was washed and total RNA was eluted
with 80 μl of pre-heated (95◦C) elution solution provided by the
manufacturer and then frozen at −80◦C.
REVERSE TRANSCRIPTION
Individual miRNA RT
miRNAs were reverse-transcribed using the TaqMan® microRNA
RT kit (Applied Biosystems, USA, #4366596) and the associated
miRNA-speciﬁc stem-loop primers (TaqMan® microRNA assay
kit, #4427975). Total RNA from muscle was diluted at a concentra-
tion of 12.5 ng/μl and 4 μl of RNA were added to the reaction mix
containing 0.15 μl 100 mM dNTP, 1 μl enzyme (50 U/μl), 1.5 μl
10× RT buffer, 0.19 μl RNase inhibitor (20 U/μl), 1.5 μl 5× RT
speciﬁc-primer and 7.66 μl DEPC-treated water to obtain a ﬁnal
volume of 15 μl. The used primer concentration is twofold lower
than the concentration recommended by ABI. In order to save
reagent, we evaluated the possibility to reduce the primer concen-
tration and tested the effect of a twofold primer dilution. Results
showed that reducing the ﬁnal concentration of primers only had
a minor impact on the detection threshold, which increased from
less than 0.5 cycles (data not shown). Thus, primer was used at
a ﬁnal concentration of 0.5× for all further analyzes. Concern-
ing the RT of plasma miRNAs, due to the low plasma miRNA
expression levels, a ﬁxed volume of 3 μl of the 80 μl plasma RNA
eluate was used as input in the reaction mix described above. RT
reaction conditions were as follows: 30 min at 16◦C to anneal
primers, 30 min at 42◦C for the extension of primers on miRNA
and the synthesis of the ﬁrst cDNA strand, 5 min at 85◦C to stop
the reaction. cDNA was then stored at −20◦C until use.
Multiple miRNA reverse transcription
miRNAs were reverse-transcribed using the TaqMan® microRNA
RT kit (#4366596) and the associated miRNA-speciﬁc stem-loop
primers (TaqMan® microRNA assay kit, #4427975) with some
modiﬁcations. A customized RT primer pool was prepared by
pooling all miRNA-speciﬁc stem-loop primers of interest. In brief,
miRNA-speciﬁc primerswere pooled anddiluted in 1×Tris-EDTA
(TE) buffer to obtain a ﬁnal dilution of 0.05× each. 6 μl of this
mixture were added to the reaction mix containing 0.3 μl 100 mM
dNTP, 3 μl enzyme (50 U/μl), 1.5 μl 10× RT buffer, 0.19 μl
RNase inhibitor (20 U/μl) and 50 ng of muscle total RNA or 3 μl
of plasma RNA. A ﬁnal volume of 15 μl was reverse-transcribed
with the following conditions: 30 min at 16◦C to anneal primers,
30 min at 42◦C for the extension phase, 5 min at 85◦C to stop the
reaction. cDNA was then stored at −20◦C.
PRE-AMPLIFICATION
In order to increase the amount of cDNA and to improve the
sensitivity of theTaqMan® qPCRreaction, aPA stepwasperformed
onplasma cDNAs. PAPCR conditions consisted in 10min at 95◦C,
2 min at 55◦C, 2 min at 72◦C, followed by 13 cycles of 15 s at 95◦C,
4 min at 60◦C and 10 min at 99.9◦C. At the end of the run, the PA
products were diluted 4× in 0.1× TE buffer pH 8.0 and stored at
−20◦C.
Individual cDNA pre-ampliﬁcation mix
Protocol for the individual cDNA PA mix was as described by
manufacturer. Brieﬂy, the PA reaction combined 2 μl of RT prod-
uct with 10 μl 2× TaqMan® PreAmp Master Mix (#4391128),
2 μl 10× Megaplex Preamp primers V2.1 (#4399233) and 6 μl
DEPC-treated water.
Multiple cDNAs pre-ampliﬁcation mix
To simultaneously pre-amplify multiple cDNAs, we created a
PA primer pool targeting the same miRNAs that were reverse-
transcribed and containing 5 μl of each individual 20× TaqMan®
Small RNA Assay (part of #4427975) diluted in 500 μl 1× TE. The
reactionmixwas prepared by combining 3.75μl of PAprimer pool
with 2.5 μl of RT product, 12.5 μl of 1× TaqMan® Universal PCR
MasterMix (2×), no UNG (#4440040) and 6.25 μl DEPC-treated
water.
REAL-TIME QUANTITATIVE PCR
All RT-qPCRs were carried out in triplicate with ABI products
and were performed on the MX3000p thermal cycler system from
Stratagene with the following conditions: one denaturing step at
95◦C for 10 min, followed by 40 cycles consisting of denaturing
at 95◦C for 15 s and annealing and elongation at 60◦C for 60 s,
followed by an inactivation step of 10 min at 99.9◦C. qPCR target
sequences are provided in Table 1.
Table 1 | List ofTaqMan® miRNAs and snoRNAs used in this study.
Name Assay ID Target sequence
hsa-miR-1 002222 UGGAAUGUAAAGAAGUAUGUAU
hsa-miR-15a 000389 UAGCAGCACAUAAUGGUUUGUG
hsa-miR-16 000391 UAGCAGCACGUAAAUAUUGGCG
hsa-miR-20a 000580 UAAAGUGCUUAUAGUGCAGGUAG
hsa-miR-21 000397 UAGCUUAUCAGACUGAUGUUGA
hsa-miR-126 002228 UCGUACCGUGAGUAAUAAUGCG
hsa-miR-133a 002246 UUUGGUCCCCUUCAACCAGCUG
hsa-miR-146a 000468 UGAGAACUGAAUUCCAUGGGUU
hsa-miR-210 000512 CUGUGCGUGUGACAGCGGCUGA
hsa-miR-221 000524 AGCUACAUUGUCUGCUGGGUUUC
hsa-miR-222 002276 AGCUACAUCUGGCUACUGGGU
hsa-miR-454 002323 UAGUGCAAUAUUGCUUAUAGGGU
hsa-miR-486 001278 UCCUGUACUGAGCUGCCCCGAG
hsa-miR-494 002365 UGAAACAUACACGGGAAACCUC
RNU44 001094 CCUGGAUGAUGAUAGCAAAUGCUGACUGAA
CAUGAAGGUCUUAAUUAGCUCUAACUGACU
RNU48 001006 GAUGACCCCAGGUAACUCUGAGUGUGUCG
CUGAUGCCAUCACCGCAGCGCUCUGACC
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Table 2 | Improvement of sensitivity through pre-amplification (PA) step on individual and pooled cDNA.
Individual cDNA Pooled cDNAs
w/o PA (CT) With PA (CT) Differencies w/o PA (CT) With PA (CT) Differencies
miR-16 25.83 17.72 8.1 28.73 20.64 8.1
miR-20a 30.77 21.82 8.9 30.96 23.67 7.3
miR-146a 31.40 23.21 8.2 34.57 26.35 8.2
miR-454 32.53 24.89 7.6 35.05 26.66 8.4
RT-qPCR with individual cDNA
Real-time PCR reactions were modiﬁed for a smaller ﬁnal volume
of 15 μl per well, using the same reagent proportions as recom-
mended by themanufacturer. In eachwell, 1μl of muscle cDNAor
1.5 μl of diluted PA plasma cDNA was added to the reaction mix
containing 0.75× TaqMan® Small RNA Assay (20×; #4427975)
and 0.75× TaqMan® Universal PCR MasterMix (2×), no UNG
(#4440040). Plates were mixed by hand and brieﬂy centrifuged
before being loaded onto the qPCR machine.
RT-qPCR with multiple cDNAs
Real-timePCRreactionswithmultiple cDNAswereperformed in a
20μl ﬁnal volume. A reactionmix containing 0.2μl of multiplexed
muscle cDNAs or 0.2 μl of pre-ampliﬁed plasma cDNAs, 7.5 μl
2× TaqMan® Universal PCR MasterMix, no UNG (#4440040)
and 11.3 μl DEPC-water was loaded in each well and 1 μl of
1× TaqMan® Small RNA Assay (20×; #4427975) was added. The
used MasterMix concentration is 25% lower than recommended
byABI. Previous experiments fromour labdemonstrated that such
reduction of theMasterMix concentration did not inﬂuence detec-
tion thresholds. Plates were mixed by hand and brieﬂy centrifuged
before being loaded onto the qPCR machine.
RESULTS
PRE-AMPLIFICATION STEP
As expected, the PA step signiﬁcantly reducedCTdetection thresh-
old in both individual and pooled experiments. Table 2 shows the
CT values for the two conditions aforementioned and the dif-
ferences in CT for the four miRNAs selected. In our hands we
observed an average of 8.2 and 8.0 cycles difference for individual
and pooled cDNA, respectively.
SENSITIVITY AND SPECIFICITY
The sensitivity of miRNA quantiﬁcation in muscle and plasma
using the customized TaqMan® miRNA Assay protocol was eval-
uated by a dose-response curve for each miRNA used in the RT
primer pool. The RT primer pool for muscle analysis consisted in
miR-1, miR-15a, miR-16, miR-21, miR-126, miR-133a, miR-210,
miR-221, miR-222, RNU44, and RNU48. In the same manner, the
RT primer pool for plasma analysis consisted in miR-16, miR-20a,
miR-21, miR-126, miR-133a, miR-146a, miR-210, and miR-454.
The protocol described in this manuscript is based on a ﬁxed vol-
ume of RT product to be used in the PCR reaction. Therefore,
increasing the cDNA input requires to increase the RNA amount
used in the RT reaction. This explains why the standard curve was
based on RNA dilution and not cDNA.A standard curve including
5 RNA dilution points (5, 10, 50, 100, and 200 ng of total RNA)
was established for themiRNAsof interest present inmuscle tissue.
This represents a dilution of cDNA ranging from 0.067 to 2.6 ng.
The low amount of RNA in plasma prevents standard RNA quan-
tiﬁcation via optical densitymeasurement. Thus, a ﬁxed volume of
plasma RNA was used to perform a standard curve ranging from 1
to 4μl of plasmaRNA.All dilutionpointswere reverse-transcribed
separately before being ampliﬁed for each miRNA. All tested miR-
NAs were successfully ampliﬁed in both muscle and plasma. The
efﬁciency and the coefﬁcient of determination (R2) were deter-
mined from the standard curve for each miRNA present in the RT
primer pool. The R2 of qPCR reactions on muscle samples were
higher than 0.993 (Figure 2A) with efﬁciency ranged from 94.9 to
166.6%. The R2 of qPCR reactions on plasma samples were higher
FIGURE 2 | (A) Standard curves from 11 miRNAs expressed in human
muscle tissue. (B) Standard curves from eight microRNAs (miRNAs)
expressed in human plasma samples.
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than 0.960 (Figure 2B) with efﬁciency ranged from 88.5 to 119.1%
(Table 3). These results demonstrate a good linearity of the dif-
ferent assays and the fact that the ﬁrst point of the standard curve
is as low as 5 ng RNA (corresponding to predicted cDNA inputs
of 0.067 ng for the multiplex method) indicates a high sensitivity
of miRNAs ampliﬁcation. The efﬁciency of these standard curves
does not only reﬂect the speciﬁcity of qPCR primers but also the
efﬁciency of the RT to convert RNA into cDNA. Indeed, standard
curves do not result from a serial dilution of a single RT product,
but from a serial dilution of a unique RNA sample, thus ﬁve RT
products. This explains why some miRNAs have an excellent lin-
earity despite of a reduced or increased efﬁciency. To verify that
the efﬁciency of miR-21 (166.6%) in muscle was not related to the
multiplexing method, we completed a standard curve following
an individual RT of miR-21. Results showed an efﬁciency largely
superior to 100% as well (142%, R2 = 0.95), suggesting that the
efﬁciency of miR-21 in the multiplexing protocol is not related
to the method. Together, these results revealed that the presence
of multiple miRNA-speciﬁc stem-loop primers in the same RT
reaction mix did not alter or inhibit the RT reaction by non-
speciﬁc interactions. Moreover, the presence of multiple cDNA
species in the qPCR reaction mix did not inﬂuence the speci-
ﬁcity of the ampliﬁcation. Furthermore, a no template control
(NTC) was run for each miRNA to rule out cross contaminations
of reagents or surfaces. No ampliﬁcation curves were observed for
any NTC,while all 60 assays were successfully ampliﬁed suggesting
the absence of non-speciﬁc interactions.
REPEATABILITY
Intra-assay variability was tested to assess the repeatability
of the assay. Three independent RTs were performed from
the same muscle RNA sample. For each aliquot, 11 muscle
Table 3 | R2 and efficiency of the standard curves obtained with the
modifiedTaqMan® Small RNAAssay.
Muscle Plasma
R2 Efficiency R2 Efficiency
mir-1 0.999 117.9 miR-16 0.986 100.0
miR-15a 0.993 110.1 miR-20a 0.988 107.0
miR-16 0.999 133.5 miR-21 0.960 110.3
miR-21 0.994 166.6 miR-126 0.993 94.4
miR-126 0.999 94.9 miR-133a 0.996 88.5
miR-133a 1.000 99.0 miR-146a 0.967 109.4
miR-210 0.996 101.0 miR-454 0.994 119.1
miR-221 0.993 133.2 miR-486 0.998 96.6
miR-222 0.996 115.7
RNU44 0.999 100.6
RNU48 0.998 101.3
R2 value is the coefﬁcient of determination of the standard curves and the
efﬁciency is the rate at which the polymerase chain reaction (PCR) amplicon
is generated. The R2 and the efﬁciency were calculated by the MxPro qPCR
Software.
miRNAs (miR-1, miR-15a, miR-16, miR-21, miR-126, miR-
133a, miR-210, miR-221, miR-222, RNU44, and RNU48)
were simultaneously reverse-transcribed and then four miRNAs
(miR-1, miR-16, miR-21, and RNU44) were ampliﬁed indi-
vidually by qPCR. Similarly, one plasma sample was divided
in three aliquots of 400 μl each and RNA was extracted as
described. For each plasma sample, eight miRNAs (miR-16,
miR-20a, miR-21, miR-126, miR-133a, miR-146a, miR-210,
and miR-454) were simultaneously reverse-transcribed and then
pre-ampliﬁed. Four plasma miRNAs (miR-16, miR-20a, miR-
146a, and miR-454) were then analyzed individually by qPCR.
The coefﬁcient of variation (CV%) was calculated to deter-
mine the intra-assay variability. The CVs ranged from 0.27 to
0.38% and from 0.21 to 0.45% for muscle and plasma sam-
ples, respectively, indicating a high reproducibility of the assay
(Table 4).
ACCURACY
To assess the accuracy of the RT-qPCR system described
herein, we show that the inter-subject expression variabil-
ity for one speciﬁc miRNA is similar in the individual and
pooled method. Therefore, we extracted RNA from four mus-
cle and four plasma samples. Eight miRNAs used for the
repeatability experiment in muscle (miR-1, miR-16, miR-21,
and RNU44) and plasma (miR-16, miR-20a, miR-146a, and
miR-454) were reverse-transcribed in each sample, once indi-
vidually and once pooled in the same RT. After the ampliﬁ-
cation of these cDNAs, we observed that the individual cycle
threshold (CT) values differed depending on the RT approach
chosen. The use of reagents at different volumes and con-
centrations in the RT reaction explains these variations. It
is however expected that the ratio CT (pooled cDNAs)/CT
(individual cDNA) remains stable. The coefﬁcient of varia-
tion (CV%) of this ratio was calculated for each reaction. The
inter-assay CVs ranged from 0.5 to 2.3% and from 1.2 to
3.0% for muscle and plasma samples, respectively (Table 5),
indicating that the CT value of the miRNAs ampliﬁed with
Table 4 | Intra-assay repeatability of the modifiedTaqMan® Small RNA
Assay.
Aliquot 1 Aliquot 2 Aliquot 3
CT CT CT Average CT SD CV %
Muscle
miR-1 25.93 25.81 25.93 25.89 0.07 0.27
miR-16 26.58 26.41 26.53 26.51 0.09 0.33
miR-21 34.94 35.09 35.18 35.07 0.12 0.34
RNU44 33.98 33.88 34.13 34.00 0.13 0.38
Plasma
miR-16 21.94 21.77 21.78 21.83 0.10 0.45
miR-20a 26.45 26.24 26.26 26.32 0.12 0.44
miR-146a 26.69 26.65 26.58 26.64 0.06 0.21
miR-454 28.79 28.64 28.75 28.73 0.08 0.28
www.frontiersin.org November 2014 | Volume 5 | Article 413 | 5
Le Carré et al. Multiplexing reverse transcription for microRNAs quantiﬁcation
Table 5 | Coefficient of variation (CV%) of the ratio CT (pooled cDNAs)/CT (individual cDNA).
Ratio CT pooled/individual method
Sample 1 Sample 2 Sample 3 Sample 4 Average SD CV %
Muscle
miR-1 1.43 1.38 1.42 1.42 1.41 0.02 1.8
miR-16 1.20 1.19 1.18 1.16 1.18 0.02 1.3
miR-21 1.36 1.38 1.33 1.31 1.35 0.03 2.3
RNU44 1.29 1.29 1.29 1.28 1.29 0.01 0.5
Plasma
miR-16 1.24 1.19 1.28 1.22 1.23 0.04 3.0
miR-20a 1.27 1.25 1.29 1.26 1.26 0.02 1.6
miR-146a 1.15 1.19 1.20 1.19 1.18 0.02 1.7
miR-454 1.12 1.12 1.14 1.14 1.13 0.01 1.2
the pool method accurately reﬂects the expected levels of
expression.
CONCLUSION
The individual analysis of multiple miRNAs is time and
reagent consuming. Here, we describe an approach allow-
ing to simultaneously measure multiple miRNAs in muscle
and plasma samples. To our knowledge this method was
never described in the literature whereas ABI published on
their web site a protocol for creating custom RT pools using
TaqMan® microRNA Assays. In this way, we validate and
bring minor adaptations to a technique allowing to multi-
plex the RT and PA steps. Validation results show that this
customized method is not only sensitive and highly speciﬁc
but also repeatable and accurate. In addition, the adapta-
tions brought to the original protocol allow to save expensive
reagents, such as stem-loop primers, MasterMix and PA mix,
as well as time by eliminating the PA step for every tissue but
plasma.
Lao et al. (2006) previously described an elegant and efﬁ-
cient multiplexing method based on TaqMan® probes that
allows the simultaneous ampliﬁcation and analysis of up to
190 miRNAs. However, this method is restricted to the
use of a pre-designed RT primer pool and therefore does
not allow the multiplex analysis of novel miRNAs that may
not be included in this pool. In contrast, our protocol
allows to create a RT primer pool unique to the miRNAs
of interest. Moreover, whereas Lao et al. (2006) results must
be treated as microarray results and therefore require fur-
ther conﬁrmation by single PCR, the method we describe
here does not require this step. Our method is therefore
of high relevance to simultaneously analyze a limited num-
ber of miRNAs, selected from a previous microarray screen-
ing or from the literature, on a large number of sam-
ples. Altogether, it will facilitate the identiﬁcation and mea-
sure of speciﬁc miRNAs biomarkers and greatly contribute
to the understanding of how miRNAs regulate biological
processes.
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